Jain, N., Thompson, P., Burger, J., Ferrajoli, A., Takahashi, K., Estrov, Z., Borthakur, G., Bose, P., Kadia, T., Pemmaraju, N., Sasaki, K., Konopleva, M., Jabbour, E., Garg, N., Wang, X., Kanagal-Shamanna, R., Patel, K., Wang, W., Wang, S., Jorgensen, J., Lopez, W., Ayala, A., Plunkett, W., Gandhi, V., Kantarjian, H., O'Brien, S., Keating, M., & Wierda, W. (n.d.). s149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION. HemaSphere, 6, 50–51. http://access.bl.uk/ark:/81055/vdc_100158013756.0x000006